Custom-designed multiple ligation-dependent probe amplification (MLPA, MRC Holland) validated the array CGH findings and suggested the prevalence of duplications involving PPP2R3B to be 5% of the total cohort of 125 individuals with CMN (Fig. 1c, d), but was not as robust as CGH or NGS for duplication discovery. Here, PPP2R3B is linked to congenital mesoblastic nephroma.